None listed
Conditions
Interventions
experimental group:Take 100mg venclexta orally
Sponsors
Chinese PLA General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Voluntarily participate in the clinical research; the subject or their legal guardian fully understands and is informed about the study and signs the informed consent form; Willing to follow and able to complete all trial procedures; 2. Age at screening: 18 years <= age <= 65 years, gender (not restricted); 3. Within 7 days before the start of the study and during the study period, the subject has not used moderate or strong inducers/inhibitors of CYP3A4, CYP2C19, OATP1B3, P-gp, including products such as grapefruit and coffee; 4. No severe allergic constitution; 5. Liver function: ALT and AST <= 2.5 times the upper limit of normal, bilirubin <= 2 times the upper limit of normal; 6. Renal function: Creatinine <= upper limit of normal;
Exclusion criteria
Exclusion criteria: 1. Subjects with allergies or contraindications to the investigational drug; 2. Pregnant or breastfeeding female subjects; 3. Subjects who smoke or chronically consume alcohol to an extent that may affect the evaluation of trial results; 4. Severe infections that are difficult to control; 5. Subjects who are unable to provide informed consent or cooperate with the completion of treatment and examination procedures due to mental illness or other medical conditions; 6. Subjects who have undergone major organ surgery within the past 6 weeks; 7. Subjects deemed unsuitable for this clinical trial by the investigator (e.g., poor compliance, drug abuse, etc.)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AUC of venclexta;Plasma concentration of Voriconazole;Plasma concentration of Posaconazole;Tmax of venclexta;Cmax of venclexta;T1/2 of venclexta;CL/F of venclexta; | — |
Countries
China
Contacts
Public ContactDaihong Liu
Chinese PLA General Hospital
Outcome results
None listed